Institutional frameworks and innovation in the German and UK pharmaceutical industry

被引：61

作者：

Casper, S

Matraves, C ^{[1
]}

机构：

[1] Michigan State Univ, Dept Management, E Lansing, MI 48824 USA

[2] Univ Cambridge, Judge Inst Management Studies, Cambridge CB2 1AG, England

[3] Albion Coll, Dept Econ & Management, Albion, MI 49224 USA

来源：

RESEARCH POLICY | 2003年 / 32卷 / 10期

关键词：

institutional frameworks; innovation; pharmaceuticals;

D O I：

10.1016/S0048-7333(03)00082-9

中图分类号：

C93 [管理学];

学科分类号：

12 ; 1201 ; 1202 ; 120202 ;

摘要：

This paper analyzes how governance structures impact the innovation capabilities of leading German and UK firms in the pharmaceutical industry. Our main objective is to show how variation in national institutional frameworks influences the innovation process, and thus, relative performance. There are two main conclusions. First, the corporate governance structure allowed leading UK firms to more quickly adapt than German firms to rapidly changing external environmental conditions in the global pharmaceutical industry. Secondly, leading UK firms have an advantage in generating innovative drugs ("blockbusters") than do German firms due to the nature of the institutional framework in which they are embedded. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：1865 / 1879

页数：15

共 49 条

[41]

*VFA, 2002, PHARM IND GERM

[42]

VITOLS S, 2002, COMPET CHANG, V6, P309, DOI DOI 10.1080/10245290215047

[43]

Vitols S., 2001, VARIETIES CAPITALISM

[44]

*WELLC TRUST, 1998, 9 WELLC TRUST

[45]

Williamson OliverE., 1985, The Economic Institutions of Capital

[46]

WIRTSCHAFTSWOCH, 1997, UNMUT NERVOSITAT, P52

[47]

Woolcock S., 1997, CORPORATE GOVERNANCE

[48] Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm [J].

Zucker, LG ;

Darby, MR .

RESEARCH POLICY, 1997, 26 (4-5) :429-446

[49]

1997, DTSCH BUNDESBANK

← 1 2 3 4 5 →